An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation

The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS).
The name of the study drugs involved in this study are:
Belumosudil (an immunotherapy)
Fluticasone (an intranasal corticosteroid)
Azithromycin (an antibiotic)
Montelukast (a leukotriene receptor antagonist)
Prednisone (a corticosteroid)

开始日期2024-05-31

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+2]

NCT06290102 / Recruiting临床1期

An Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler With e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants With Asthma (4 to 11 Years Old)

The primary objectives of this study are:
To determine the pharmacokinetic (PK) profile of fluticasone propionate (Fp) and albuterol sulfate (ABS), delivered in combination, from a single dose of TEV-56248 (Fp and ABS multidose dry powder inhaler with e-module [Fp/ABS eMDPI]) in participants with asthma
To compare the PK profiles of Fp for 2 different dose strengths of TEV-56248 to that of fluticasone propionate multidose dry powder inhaler (Fp MDPI)
To compare the PK profiles of ABS between the 2 different strengths of TEV-56248
The secondary objective is:
• To evaluate the safety of a single dose of TEV-56248 and a single dose of Fp MDPI

开始日期2024-05-07

申办/合作机构

Teva Branded Pharmaceutical Products R&D, Inc.

CTR20241831 / RecruitingN/A

丙酸氟替卡松乳膏的人体生物等效性研究

1、以健康受试者为研究对象，以参比制剂丙酸氟替卡松乳膏（商品名：Cutivate®，规格：0.05% 15g:7.5mg/支，GlaxoSmithKline (Ireland) Limited公司持证）为试验用药，通过观测收缩皮肤血管，致使皮肤变白的作用，探索达到半数最大效应（Emax）的剂量持续时间（ED50）；2、以健康受试者为研究对象，通过观测皮肤血管收缩，比较受试制剂丙酸氟替卡松乳膏（规格：0.05% 15g:7.5mg/支，浙江仙琚制药股份有限公司）与参比制剂丙酸氟替卡松乳膏（商品名：Cutivate®，规格：0.05% 15g:7.5mg/支，GlaxoSmithKline (Ireland) Limited公司持证）致使皮肤变白的作用，评价受试制剂与参比制剂是否具有生物等效性。

开始日期2024-04-20

申办/合作机构

浙江仙琚制药股份有限公司

100 项与丙酸氟替卡松相关的临床结果

登录后查看更多信息

100 项与丙酸氟替卡松相关的转化医学

登录后查看更多信息

100 项与丙酸氟替卡松相关的专利（医药）

登录后查看更多信息

4,061

项与丙酸氟替卡松相关的文献（医药）

2024-04-01·Journal of glaucoma

Effect of Glucosamine on Intraocular Pressure and Risk of Developing Glaucoma

Article

作者: Danias, John ; Rheinstein, Peter H ; Karrasch, Charles ; Morello, Timothy ; Lehrer, Steven

Précis::

Glucosamine supplementation is common but can be associated with increased intraocular pressure (IOP) and could contribute to the pathogenesis of glaucoma. It may be prudent for ophthalmologists to elicit any history of glucosamine use from their patients and advise them accordingly. Further studies on the role of glucosamine in glaucoma are warranted.

Background::

The most frequently recommended slow-acting medication for osteoarthritis symptoms is glucosamine, although its effectiveness is questionable. Widely used glucosamine sulfate supplements may increase IOP.

Methods::

In the current study, we analyzed online databases such as UK Biobank, MedWatch, and FinnGen to evaluate the relationship between glucosamine and IOP and glaucoma. We included budesonide and fluticasone in the analysis for comparison since these drugs are associated with increased IOP.

Results::

In UK Biobank subjects, glucosamine use was associated with increased corneal compensated IOP (P=0.002, 2-tailed t test). This was also true in subjects without glaucoma (P=0.002, 2-tailed t test). However, no significant association between glucosamine and IOP was detected in subjects with a diagnosis of glaucoma. In MedWatch, 0.21% of subjects taking glucosamine reported glaucoma, 0.29% of subjects using budesonide reported glaucoma, and 0.22% of subjects using fluticasone reported glaucoma. In contrast, 0.08% of subjects using any other drug reported glaucoma. This variability is significant (P<0.001, 2-tailed Fisher exact test). Data from FinnGen on the risk of primary open angle glaucoma or glaucoma in subjects using glucosamine before the diagnosis of the disease revealed a significantly increased risk for both primary open angle glaucoma (hazard ratio: 2.35) and glaucoma (hazard ratio: 1.95).

Conclusion::

Glucosamine supplementation is common but can be associated with increased IOP and could contribute to the pathogenesis of glaucoma. It may be prudent for ophthalmologists to elicit any history of glucosamine use from their patients and advise them accordingly. Further studies on the role of glucosamine in glaucoma are warranted.

2024-03-01·Advances in therapy

Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials

Article

作者: Majumdar, Anurita ; Yorgancıoğlu, Arzu ; Pitrez, Paulo M ; Della Pasqua, Oscar ; Brusselle, Guy ; Fumali, Sourabh ; Oosterholt, Sean ; van Dijkman, Sven C ; Pavord, Ian

INTRODUCTION:

Even though increased use of reliever medication, including short-acting beta agonists (SABA), provides an indirect measure of symptom worsening, there have been limited efforts to assess how different patterns of reliever use correlate with symptom control and future risk of exacerbations. Here, we evaluate the effect of individual baseline characteristics on reliever use in patients with moderate-severe asthma on regular maintenance therapy with fluticasone propionate (FP) or combination therapy with fluticasone propionate/salmeterol (FP/SAL) or budesonide/formoterol (BUD/FOR).

METHODS:

A drug-disease model describing the number of 24-h puffs and overnight occasions was developed with data from five clinical studies (N = 6212). The model was implemented using a nonlinear mixed effects approach and a Poisson function, considering clinical and demographic baseline characteristics. Goodness of fit and model predictive performance were assessed. Heatmaps were created to summarise the effect of concurrent baseline factors on reliever utilisation.

RESULTS:

The final model accurately described individual patterns of reliever use, which is significantly increased with time since diagnosis, smoking, higher Asthma Control Questionnaire (ACQ-5) score and higher body mass index (BMI) at baseline. Whilst the number of puffs decreases slowly after an initial drop relative to the start of treatment, exacerbating patients utilise significantly more reliever than those who do not exacerbate. The mean effect of FP/SAL (median dose: 250/50 μg BID) on reliever use was slightly higher than that of BUD/FOR (median dose: 160/4.5 μg BID), i.e. a 75.3% vs 69.3% reduction in reliever use, respectively.

CONCLUSIONS:

The availability of individual-level patient data in conjunction with a parametric approach enabled the characterisation of interindividual differences in the patterns of reliever use in patients with moderate-severe asthma. Taken together, individual demographic and clinical characteristics, as well as exacerbation history, can be considered an indicator of the degree of asthma control. High SABA reliever use suggests suboptimal clinical management of patients on maintenance therapy.

2024-03-01·Pulmonary therapy

Correction: A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis

作者: Cheng, Lei ; Lin, Peng ; Zhou, Huifang ; Ramalingam, Rajesh Kumar ; Fang, Hongyan ; Tan, Guolin ; Wang, Huizhong ; Nguyen, Duc Tung ; Jin, Yongde ; Zhao, Changqing ; Zhang, Hua ; Zhou, Bing ; Dong, Yaowu ; Kuhl, Hans Christian ; Pan, Jing

234

项与丙酸氟替卡松相关的新闻（医药）

2024-07-01

·药闻康策

药闻康策会员医药资源信息共享区(0701）

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策 2024 0701 药品高端会员区 HOT 高端会员1 【会员编号】y1172 【所在地区】北京，河北，山西【所在公司】黑龙江久久药业有限责任公司【工作职务】河北山西招商经理【相关产品】 ①【香砂养胃颗粒】基药，独家无蔗糖，国家专利保护剩余19年，医保甲，OTC乙。 ②【刺五加颗粒】独家剂型无蔗糖，医保乙，OTC甲。 ③【小儿清热止咳口服液】妇儿急抢目录，医保乙，OTC甲。 ④【健儿消食口服液】基药，医保乙，OTC甲。【自身资源】基独家，基药【需要资源】河北，山西三终端，或临床代理高端会员2 【会员编号】y1199 【所在地区】吉林省【所在公司】长春海悦药业有限公司【工作职务】省区经理【相关产品】海悦美奥，悦思立普，伏立康唑，丙戊酸钠注射用浓溶液，他达拉非，注射用阿奇霉素（儿童），曲克芦丁，盐酸氨溴索，盐酸美金刚等【自身资源】吉林省内分泌专家以及医院资源，商业公司合作资源（大商业以及地方商业）；吉林省慢病产品市场布局及推广策略（策略层面）【需要资源】吉林省及东北三省的准入资源，消化内科准入以及一线客户资源（多方式合作）；阿奇霉素注射液市场分析报告（成人&儿童）、奥美拉唑市场分析报告高端会员3 【会员编号】y1211 【所在地区】陕西【所在公司】北京轩竹生物科技有限公司【工作职务】省区经理【相关产品】安奈拉唑钠【自身资源】政府事务（医保局）核心医院ICU临床【需要资源】医院准入药剂关系代理商高端会员4 【会员编号】y1198 【所在地区】川渝藏【所在公司】江西青峰药业有限公司【工作职务】省区经理【相关产品】艾司奥美拉唑镁肠溶片、枸橼酸托法替布片、阿哌沙班片、富马酸丙酚替诺福韦片、恩替卡韦分散片/胶囊、盐酸乌拉地尔注射液、阿普米司特片、雷贝拉唑钠肠溶片、枳实总黄酮片。【自身资源】政府事务，四川省消化专家以及医院资源，商业公司合作资源【需要资源】一线客户资源和代理商资源高端会员5 【会员编号】y1087 【所在地区】湖南【所在公司】清华德仁西安幸福制药有限公司【工作职务】大区经理【相关产品】生血宝合剂、五灵胶囊、热炎宁合剂、童康颗粒【自身资源】厂家产品资源【需要资源】临床类型代理商：湖南省级代理商；湖南省地区代理商。高端会员6 【会员编号】y0134 【所在地区】北京【所在公司】北京杏林知松科技有限公司【工作职务】销售总监【相关产品】环磷腺苷葡胺、益心胶囊、盐酸曲马多分散片【自身资源】北京临床渠道多年、全国总代产品【需要资源】各省总代资源、厂家资源高端会员7 【会员编号】y1150 【所在地区】贵州【所在公司】贵州佳德同汇健康咨询服务有限公司【工作职务】业务负责人【相关产品】安奈拉唑钠肠溶片、头孢呋辛钠氯化钠注射液、甘草酸单铵半胱氨酸氯化钠注射液等三十几个产品【自身资源】贵州省代。贵州部分医院资源，产品资源。【需要资源】有医院资源的客户，需具备开发能力。可提供品种和资金。高端会员8 【会员编号】y0855 【所在地区】北京【所在公司】北京伟林恒昌医药科技有限公司【工作职务】总经理【相关产品】自己持有:阿托伐他汀钙片，奥洛他定片【自身资源】招商和对外贴牌生产【需要资源】需要各省OTC销售团队高端会员9 【会员编号】y1002 【所在地区】北京【所在公司】国药控股北京有限公司【工作职务】采购中心市场部经理【相关产品】药品、器械等【自身资源】北京招采信息【需要资源】全国招采信息高端会员10 【会员编号】y1142 【所在地区】江苏南京【所在公司】凡森特医药【工作职务】销售总监【相关产品】抗生素/化药/器械/中成药【自身资源】渠道、产品、学术【需要资源】客户、渠道高端会员11 【会员编号】y1193 【所在地区】北京【所在公司】北京康辰生物【工作职务】法务合规经理【相关产品】原研药品-骨松骨痛相关【自身资源】药械合规及法律相关【需要资源】关于医药行业的合规及法律相关的信息高端会员12 【会员编号】y0317 【所在地区】湖南长沙【所在公司】湖南广药恒生医药有限公司【工作职务】采购总监【相关产品】一类麻精产品【自身资源】广药集团国企、有一类麻精配送资质、全省医疗机构覆盖配送、新品开发进院能力较强、招商产品可协助推广。【需要资源】医院自营产品、零售分销业务全省配送。高端会员13 【会员编号】y1128 【所在地区】云南省昭通市【所在公司】云南蓝蝶医疗器械有限公司【工作职务】总经理【相关产品】医疗产品【自身资源】昭通市及昭通周边地区的客户资源【需要资源】优质的医疗产品，及其他地州的客户资源高端会员14 【会员编号】y1226 【所在地区】四川成都【所在公司】四川启源药业有限公司【工作职务】总监【相关产品】医保甲类基药【自身资源】厂家临床基药医保产品【需要资源】江西省区临床团队及省第三终端资源高端会员15 【会员编号】y1187 【所在地区】南京【所在公司】悦康药业【工作职务】招商经理【相关产品】活心丸【自身资源】基药，甲类，安全性高【需要资源】江苏地区招商高端会员16 【会员编号】y1116 【所在地区】福建（主战区）江西、浙江、江苏【所在公司】康美药业股份有限公司【工作职务】区域经理【相关产品】厂家直销，包含中药饮片、燕窝虫草等贵系礼品【自身资源】1.国家膏方丸剂代煎等试点单位以及集采中标单位之一；2.可自产600多个品种上万个品规；3.可根据医院要求定制高标及小包装饮片；4.药剂科资源【需要资源】1、福建、江西、浙江、江苏区域的代理商；2、各大医院及中医馆高层资源高端会员17 【会员编号】y1140 【所在地区】北京【所在公司】吉林天衡药业有限公司【工作职务】市场运营部部长【相关产品】铝碳酸镁咀嚼片、瑞舒伐他汀钙片、秋水仙碱片【自身资源】可合作CRO、CMO、CDMO 【需要资源】销售代理商；寻找生产场地：片剂，适应症为痛风，特点是该原料为细胞毒药物，寻求细胞毒专线或可与细胞毒药物共线的生产场地。高端会员18 【会员编号】y0584 【所在地区】天津【所在公司】天津市医药集团泰宁医药【工作职务】市场总监【相关产品】狗皮膏、护肝胶囊、更年安胶囊、连翘败毒片、葡萄糖酸钙片等基药品种，全国多个省和直辖市已中标【自身资源】熟悉国各省招投标政府事务，有成熟的全国销售网络【需要资源】急需各省和直辖市的临床团队高端会员19 【会员编号】y0907 【所在地区】北京、天津【所在公司】海诚医药集团有限公司【工作职务】省区经理【相关产品】肌苷注射液（静注）、龙血竭胶囊（肠溶）、强力枇杷露（炼蜜）、磷酸川芎嗪注射液（供静脉注射用）、注射用伏立康唑、甘油灌肠剂、注射用哌拉西林钠、注射用头孢唑肟钠、注射用头孢哌酮钠舒巴坦钠、注射用氨苄西林钠舒巴坦钠、曲克芦丁注射液、核黄素磷酸钠注射液、注射用尼麦角林等产品【自身资源】全国总代理产品资源【需要资源】寻临床代理商、省总、地总团队合作高端会员20 【会员编号】y1219 【所在地区】内蒙古【所在公司】源浩医疗【工作职务】总经理【相关产品】处方药【自身资源】整个乌兰察布市二级医院、卫生院、诊所资源【需要资源】独家基药、集采品种、OTC控销产品厂家资源高端会员21 【会员编号】y0947 【所在地区】江西南昌【所在公司】江西金耐康医药科技有限公司【工作职务】经理【相关产品】神外、妇产、肿瘤领域产品【自身资源】福建和江西省代和医院客户资源，江西神经外科及妇产科专家资源【需要资源】厂家岗位或产品高端会员22 【会员编号】y1197 【所在地区】辽宁【所在公司】辽宁好护士集团医药有限公司【工作职务】省区经理【相关产品】肾炎温阳片、肾炎解热片【自身资源】独家，挂网，空间好【需要资源】操作肾病产品的医院资源团队高端会员23 【会员编号】y1096 【所在地区】河南【所在公司】浙江仙琚制药【工作职务】招商大区【相关产品】屈螺酮炔雌醇片（||）【自身资源】河南、河北、江西、安徽、北京、天津等地重点医院客户资源【需要资源】河南、河北、江西、安徽、北京、天津等地妇科团队资源高端会员24 【会员编号】y1264 【所在地区】枣庄市【所在公司】某医药公司【工作职务】经理【相关产品】肿瘤药【自身资源】等级医院客户【需要资源】最新化药产品资源高端会员25 【会员编号】y0321 【所在地区】厦门、上海【所在公司】承葛医药集团【工作职务】项目经理【相关产品】微生态移植及相关产业【自身资源】微生态检测、移植、微生态口服产品、微生态研发【需要资源】各类医药资源高端会员26 【会员编号】y1221 【所在地区】广东【所在公司】陕西盘龙药业集团【工作职务】省区经理【相关产品】1、盘龙七片（骨科）全国独家专利产品、医保甲类无后缀。2、骨松宝片（预防更年期骨质疏松症）。3、克比热提片（独家口服，皮肤科）4、复方醋酸绵酚片（妇科) 【自身资源】独家、商业公司合作资源【需要资源】医院准入、广东临床类型代理商高端会员27 【会员编号】y1278 【所在地区】陕西【所在公司】西安典茂轩医药科技【工作职务】总经理【相关产品】雾化全系列，抗生素、心脑血管领域产品。【自身资源】陕西省招商全渠道和连锁OTC自营团队及政务商业资源【需要资源】集采药，国谈化药，进口化药高端会员28 【会员编号】y1114 【所在地区】四川/西藏【所在公司】浙江孚诺/浙江惠迪森【工作职务】市场/销售主管【相关产品】复方多黏菌素B软膏/注射用拉氧头孢钠【自身资源】1.四川省皮肤科、烧伤科、肛肠科深耕细作10年建立上层专家资源，临床一线专人覆盖，自建团队，高效专业；2.四川、西藏都有自己的分销渠道，西藏有自己的商业配送公司，承接全国产品。【需要资源】1.寻找相关科室品种，签总代、有潜力的专科品种；2.寻找省内手术科室合作伙伴，推广外用抗生素品种在四川的销售。高端会员29 【会员编号】y1294 【所在地区】浙江【所在公司】浙江天啬生物医药有限公司、杭州端本医院科技有限公司【工作职务】招商经理【相关产品】主营产品线：骨科，麻醉科，消化科；自有持证：氟比洛芬凝胶贴膏【自身资源】1、浙江省临床品种推广网络;2、自有批文【需要资源】1、全国省级代理合作伙伴；2、浙江省代理推广甲方产品高端会员30 【会员编号】y1312 【所在地区】重庆【所在公司】重庆旭达药业【工作职务】总经理【相关产品】补肾健脾口服液、食积口服液【自身资源】产品资源、团队资源【需要资源】产品品牌输出高端会员31 【会员编号】y0857 【所在地区】河北【所在公司】京津医学【工作职务】产品经理【相关产品】养心定悸颗粒【自身资源】医学实验与研究，团队目前主要承接上市后医学临床再评价项目；临床推广，团队覆盖全国等级医疗及基层医疗招商，京津冀地区临床推广自营【需要资源】全国总代产品，最好是医保或者独家高端会员32 【会员编号】y0990 【所在地区】新疆【所在公司】新疆迈达医药有限公司【工作职务】销售总监【相关产品】OTC，临床基药产品【自身资源】具有完善的新疆省临床基药销售渠道和OTC销售渠道【需要资源】新特药，基药产品，集采产品，皮肤科基药产品需要在新疆推广的上游企业可接洽，以及OTC优秀品种，新疆市场可跨渠道运营高端会员33 【会员编号】y1176 【所在地区】广西【所在公司】洺康医疗【工作职务】总经理【相关产品】儿科、妇科、产科、乳腺、骨科、消化、内分泌、放射科中枢神经线，心脑血管线药品为主【自身资源】17个集采产品，8个非集采产品，拥有专业的一线自营推广队伍，全区招商队伍【需要资源】儿科领域，神经领域，心脑血管领域等国家集采产品及国谈，基药的新药器械高端会员区高端会员1 【会员编号】X0031 【所在地区】贵州贵阳【所在公司】贵州众鑫源科技有限公司【工作职务】总经理【相关产品】口腔辅料【自身资源】省级公立医院客户资源【需要资源】耗材，试剂，医美，口腔高端会员2 【会员编号】X0028 【所在地区】北京【所在公司】北博(北京)医疗器械有限公司【工作职务】总经理【相关产品】电热针治疗仪+耗材内热式电热针灸针【自身资源】有源医疗器械的研发、注册、代工【需要资源】诚招各省耗材代理商,有医保资源,本产品在《全国医疗服务项目技术规范(2023年版)》,需要增加或修订各省医保目录高端会员3 【会员编号】X0035 【所在地区】云南省昭通市【所在公司】云南蓝蝶医疗器械有限公司【工作职务】销售总监【相关产品】医疗器械相关产品【自身资源】云南省昭通市及昭通周边地区的客情资源【需要资源】优质的产品高端会员4 【会员编号】X0045 【所在地区】福建【所在公司】福州市东瑞医疗科技有限公司【工作职务】总经理【相关产品】狂免、破免、纤原，人用狂犬疫苗等【自身资源】福建省代，临床医学背景，部分医院、卫健及疾控部门资源【需要资源】适合急诊外科相关药品，耗材产品资源超级高端会员区超级会员1 【会员编号】w0201 【所在地区】湖南【所在公司】湖南健朗药业有限责任公司【工作职务】总经理【相关产品】自身持有奥拉西坦胶囊、奥拉西坦注射液、泮托拉唑肠溶胶囊、羟甲烟胺片等产品。【自身资源】招商和对外贴牌生产【需要资源】需要购买若干化学药品注册批文，已出批文或者即将申报的均可。超级会员2 【会员编号】w0045 【所在地区】山东东营【所在公司】山东凤凰制药股份有限公司【工作职务】普药事业部总监【相关产品】盐酸二甲双胍缓释片、苯磺酸氨氯地平片、辛伐他汀片、维格列汀片、护肝片、降脂宁片、复方丹参片、胃灵颗粒、半夏露颗粒、益母草颗粒、板蓝根颗粒、微达康颗粒、感冒清热颗粒、小儿咽扁颗粒、小儿咳喘灵颗粒、灵芝胶囊、活力胶囊、穿心莲胶囊、黄柏胶囊等【自身资源】厂家产品资源【需要资源】市县级临床业务团队超级会员3 【会员编号】w0150 【所在地区】山东【所在公司】山东天元盈康医疗科技有限公司【工作职务】销售总监【相关产品】人血白蛋白，破免，狂免，静丙，小儿复方氨基酸注射液，盐酸纳美芬，环磷腺苷等产品。【自身资源】政府事务在山东做省代17年有直营团队同时通过招商团队覆盖全省医院。【需要资源】上游厂家，国代，批文持有人，原料药超级会员4 【会员编号】w0033 【所在地区】四川成都【所在公司】四川省百草生物药业有限公司【工作职务】市场总监【相关产品】苯磺酸氨氯地平片、盐酸舍曲林胶囊、泛昔洛韦片【自身资源】通过一致性评价产品。医保甲类。基药。大部分省份已挂网。渠道终端市场管理好。【需要资源】临床、终端渠道代理商超级会员5 【会员编号】w0186 【所在地区】山东【所在公司】深圳万和制药有限公司【工作职务】销售部经理【相关产品】商品名：和安，和爽，和流，爱伦多等【自身资源】消化，肝病以及普外等领域专家资源【需要资源】政府事务相关超级会员6 【会员编号】w0163 【所在地区】广西【所在公司】广西炬邦乾承投资有限公司【工作职务】总经理【相关产品】集采中选:哌他，左氨氯地平，左卡尼汀，噻肟，呋塞米，他啶，曲松，丙戊酸钠，头孢地尼呼吸:沙丁，氟替卡松，异丙，左沙，乙酰半胱氨酸，茶碱，孟鲁司特。肾内:左卡，达肝，司维拉姆，促红，百令片。围手术期:羟考酮，纳布啡。布托啡诺。抗感染:磷霉素，哌舒，唑肟，阿奇。慢病:达格列净，格列齐特，氟伐他汀，左氨氯地平，门冬氨氯地平。心脑血管:辅酶Q10，倍他司汀，曲克芦丁，吡拉西坦，己酮可可碱。【自身资源】地方政府事务，专业推广能力，经销商储备，行业口碑认可。【需要资源】甲方产品超级会员7 【会员编号】w0160 【所在地区】内蒙古【所在公司】商贸公司【工作职务】总经理【相关产品】集采药品、集采器械、化妆品、特医食品等。【自身资源】35人销售团队【需要资源】集采药品、集采器械、化妆品、特医食品等。超级会员8 【会员编号】w0104 【所在地区】南京【所在公司】翎耀生物科技（上海）有限公司【工作职务】全国商务分销总监【相关产品】利培酮口服溶液、氨己烯酸口服溶液用散、阿托伐他汀钙片、利伐沙班片【自身资源】过评产品：医保、国谈，慢病系列【需要资源】全国临床、二三终端相关领域省级经销商、终端代理商超级会员9 【会员编号】w0127 【所在地区】山东【所在公司】山东誉众医药【工作职务】总经理【相关产品】骨科/肿瘤/抗生素/心血管/重症/透析/呼吸产品【自身资源】专业化的省级医药推广服务商。自营1条线+招商3条线+市场部1条线+集采产品专项。学术推广能力、政务关系、商业资源优秀。【需要资源】优质的相关产品升级代理。超级会员10 【会员编号】w0009 【所在地区】浙江【所在公司】浙江明晖医药有限公司【工作职务】总经理【相关产品】全国总代:阿昔洛韦颗粒、别嘌醇片；自有持证：他达拉非片【自身资源】1.浙江省临床品种推广网络；2、全国总代理产品；3、自有批文；4、零售电商公司；5、C端电商供应链【需要资源】1、需要在浙江代理推广的甲方产品；2、全国省级代理合作伙伴超级会员11 【会员编号】w0172 【所在地区】江苏南京【所在公司】西安良医网络科技集团有限公司【工作职务】营销中心负责人【相关产品】1.米墨 2.超医助手【自身资源】有一个医药互联网服务交易溯源平台“米墨”为行业发展提供新方案、新模式，为药械厂商提供深度学术推广及精准营销升级服务；以及医生资源平台“超医助手”目前大约有数百万的医疗行业从业者资源。拥有各类医疗互联网平台资源，企业资源，医药企业资源。【需要资源】链接医药企业超级会员12 【会员编号】w0173 【所在地区】上海市静安区【所在公司】上海鑫意医药科技有限公司【工作职务】董事长【相关产品】关节镇痛巴布膏、强力天麻杜仲胶囊等【自身资源】招标、医疗终端等【需要资源】需要上家优质产品，需要有管理能力的业务经理超级会员13 【会员编号】w0029 【所在地区】湖南【所在公司】湖南思达医药有限公司【工作职务】销售总监【相关产品】主营产品线：儿科，骨科，妇科，内科等【自身资源】湖南思达医药公司主营临床新药推广，团队覆盖湖南省14个地区，团队结构：地区经理10人，专业学术经理2人，商务经理2人；现有代理推广品种包含国采，省际联盟集采，基药，医保等类型，主营产品线：儿科，骨科，妇科，内科等；具备湖南药品招标准入能力。【需要资源】上游厂家，国代，批文持有人，原料商等，品种需要在湖南落地推广的。超级会员14 【会员编号】w0174 【所在地区】山西太原【所在公司】山西龙行医药【工作职务】总经理【相关产品】省代临床，OTC。呼吸科，心血管等【自身资源】地政，临床开发，OTC操作【需要资源】代理优秀品种，山西市场跨渠道运营超级会员15 【会员编号】w0202 【所在地区】广西【所在公司】广西花红药业集团有限公司【工作职务】业务部总经理【相关产品】花红胶囊，花红颗粒，消肿止痛酊，解毒生肌膏，葛根芩连丸【自身资源】独家医保，基药，企业品牌优势，全国有成熟的商务体系及招商资源【需要资源】寻求有资源的妇科，骨科，肛肠，慢创，儿科等合作优质客户超级会员16 【会员编号】w0166 【所在地区】杭州【所在公司】浙江和融达医疗技术有限公司【工作职务】董事长【相关产品】消化领域、心脑血管、骨科的药品和器械耗材【自身资源】成立了MAH上市持有人与院内制剂转化平台，成熟的全国销售网络，目前每年立项研发的药品和器械2-3个【需要资源】1、全国各省医疗器械和药品销售精英及MAH合伙人。2、一流研发机构和优秀生产企业战略合作。超级会员17 【会员编号】w0048 【所在地区】杭州【所在公司】浙江万晟药业有限公司【工作职务】总监【相关产品】蔓迪、芪明颗粒【自身资源】市场准入、政策法规【需要资源】市场准入（医保、招采）超级会员18 【会员编号】w0216 【所在地区】江苏南京【所在公司】武汉天安医药【工作职务】市场总监【相关产品】B证持有人公司，拥有泮托拉唑、奥美拉唑、倍他米松、阿托品等品种，奥美拉唑、阿托品为国采中选产品【自身资源】定位B证公司合作平台，可一起合作开发立项【需要资源】各省代理商资源，其中湖北、江苏拥有精细化招商团队，也可代理品种超级会员19 【会员编号】w0221 【所在地区】浙江【所在公司】浙江敬紫堂生物科技有限公司【工作职务】总经理【相关产品】酒制蜂胶【自身资源】全国临床和三终端代理商资源【需要资源】更多的终端资源超级会员20 【会员编号】w0133 【所在地区】河北【所在公司】河北东鼎医药科技有限公司【工作职务】销售总监【相关产品】喷他佐辛注射液、盐酸曲马多注射液、氯化钾颗粒、香丹注射液等【自身资源】河北省内完善的等级医院客户资源，包括镇痛类、心血管、抗生素等优质的销售网络。【需要资源】镇痛类产品，集采产品，高端学术产品。超级会员21 【会员编号】w0231 【所在地区】河南郑州【所在公司】河南诚济医药有限公司【工作职务】销售总监【相关产品】临床基药产品销售推广业务【自身资源】具有完善的河南省临床基药销售渠道【需要资源】在河南有新特药、基药产品需要推广销售的上游企业可接洽超级会员22 【会员编号】w0110 【所在地区】河南【所在公司】医药园区【工作职务】顾问【相关产品】三方业务；共享仓设立GSP公司【自身资源】政策红利（共享仓、按月返税）【需要资源】客户资源超级会员23 【会员编号】w0179 【所在地区】福州【所在公司】福建润辉商务管理有限公司【工作职务】总经理【相关产品】环丙沙星缓释片（悉复欢）500mg*6片/12片【自身资源】全国总代产品资源【需要资源】各省份/各区域代理商超级会员24 【会员编号】W0235 【所在地区】河北【所在公司】海南凯瑞医药【工作职务】营销总监【相关产品】首儿药业全系儿科产品【自身资源】河北、山东药械资源【需要资源】各省医药口服产品代理商，医院、诊所、零售、院外等渠道合作伙伴扫码加高端会员获取更多医药资源信息

高管变更专利到期

2024-06-27

·GlobeNewswire-Health Care

Expanded Access to XHANCE with Addition to National Commercial Formularies

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE® (fluticasone propionate) has been added to Express Scripts’ national formularies, including the National Preferred, Flex, and Basic formularies, among the largest commercial formularies in the U.S. with more than 24 million lives. “XHANCE is approved for treatment of chronic rhinosinusitis and, importantly, is the only medication approved for by far the most common type - without nasal polyps, so we are very pleased that Express Scripts has added XHANCE as a preferred option to these formularies,” said Ramy Mahmoud, MD, MPH, CEO of Optinose. “Our recently published landmark studies in chronic sinusitis, and the recent FDA approval, mark a breakthrough for doctors and patients who want safe and effective treatment for one the most common diagnoses in adult outpatient medicine. We look forward to seeing the addition of XHANCE to these Express Scripts national formularies result in increased patient access to the only evidence-based prescription treatment for this disease.” Chronic sinusitis (also referred as chronic rhinosinusitis) affects approximately 30 million adults in the United States. Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine. The ReOpen clinical trial program was the first ever controlled trial program we are aware of to demonstrate significant improvement in both symptoms and inflammation inside the sinuses for patients with chronic sinusitis, regardless of whether nasal polyps are present, and to demonstrate significant reduction in the number of acute exacerbations.1 About OptinoseOptinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn. About XHANCEXHANCE is a drug-device combination product that uses the Exhalation Delivery System™ (also referred to as the EDS®) designed to deliver a topical steroid to the high and deep regions of the nasal cavity where sinuses ventilate and drain. XHANCE is approved by the U.S. Food and Drug Administration for both the treatment of chronic rhinosinusitis without nasal polyps (also called chronic sinusitis) and chronic rhinosinusitis with nasal polyps (also called nasal polyps) in patients 18 years of age or older. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE. WARNINGS AND PRECAUTIONS: Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.Assess for decrease in bone mineral density initially and periodically thereafter. ADVERSE REACTIONS: Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥3%) are epistaxis, headache, and nasopharyngitis.Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis. DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.Please see full Prescribing Information, including Instructions for Use References James N. Palmer, Nithin D. Adappa, Rakesh K. Chandra, Greg E. Davis, Mahboobeh Mahdavinia, John Messina, Randall A. Ow, Zara M. Patel, Anju T. Peters, Harry Sacks, Rodney J. Schlosser, Raj Sindwani, Zachary M. Soler, Andrew A. White, Sarah K. Wise, Ramy A. Mahmoud, Efficacy of EDS-FLU for Chronic Rhinosinusitis: Two Randomized Controlled Trials (ReOpen1 and ReOpen2), The Journal of Allergy and Clinical Immunology: In Practice, Volume 12, Issue 4, 2024, Pages 1049-1061, ISSN 2213-2198, https://doi-org.libproxy1.nus.edu.sg/10.1016/j.jaip.2023.12.016. (https://www-sciencedirect-com.libproxy1.nus.edu.sg/science/article/pii/S221321982301365X) Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this purpose and include, among others, statements relating to the benefits of XHANCE for the treatment of chronic sinusitis (also called chronic rhinosinusitis) with and without nasal polyps; the potential for XHANCE to become a preferred option for the treatment of chronic sinusitis; the benefits of XHANCE being added to the Express Scripts’ national formularies; the benefits of the Exhalation Delivery System; and other statements regarding the Company's future operations, prospects, objectives, and other future events. Forward-looking statements are based upon management’s current expectations and assumptions and are subject to a number of risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: physician and patient acceptance of XHANCE for its new indication (treatment of adults with chronic rhinosinusitis without nasal polyps); the Company’s ability to maintain adequate third party reimbursement for XHANCE (including its new indication); potential for varying interpretation of clinical trial results of XHANCE; the prevalence of chronic sinusitis and market opportunities for XHANCE may be smaller than the Company expects; and the risks, uncertainties and other factors discussed under the caption "Item 1A. Risk Factors" and elsewhere in our most recent Form 10-K and Form 10-Q filings with the Securities and Exchange Commission - which are available at www.sec.gov. As a result, you are cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statements made in this press release speak only as of the date of this press release, and we undertake no obligation to update such forward-looking statements, whether as a result of new information, future developments or otherwise. Optinose Investor ContactJonathan Neelyjonathan.neely@optinose.com267.521.0531

上市批准临床研究

2024-06-24

·echemi

Respiratory Diseases Market Sees New Opportunities

Respiratory diseases, as a major challenge in the field of global public health, have always been the focus of the global medical community and the public. Among them, asthma and chronic obstructive pulmonary disease (COPD) as the two main types, not only affect billions of patients, but also bring a huge medical burden. However, with the deepening of medical research and the progress of science and technology, this field is ushering in unprecedented development opportunities. Traditional respiratory disease treatment methods, such as bronchodilation and anti-inflammatory treatment, can significantly alleviate the symptoms of patients in the short term, but often find it difficult to fundamentally solve the problem of chronic inflammation. Fortunately, with the in-depth study of the pathogenesis of the disease, especially the deepening understanding of the Th2 cell-mediated airway inflammation mechanism, we are now able to treat the root cause of the disease more accurately. For example, a number of targeted biological agents targeting inflammatory mediators such as IL-5 and IL-4/13 have been successively approved for marketing, providing new hope for patients with refractory asthma. These new drugs not only can more effectively control inflammation, but also reduce the side effects of traditional drugs, and improve the quality of life of patients. In the field of COPD treatment, there are also exciting developments. With the deeper understanding of the pathogenesis of COPD, new drug development has also made significant breakthroughs. For example, Brensocatib, a new drug from Insmed, has achieved success in phase 3 clinical trials. These new drugs not only can alleviate the symptoms of COPD patients, but also can improve lung function and quality of life. This breakthrough has undoubtedly brought new treatment options for COPD patients and new growth points for the respiratory disease market. However, with the expiration of patents, some well-established star drugs are facing fierce competition from generic drugs. Taking AstraZeneca's budesonide/formoterol and GlaxoSmithKline's salmeterol/fluticasone combination products as examples, these drugs have been the leaders in the respiratory disease market in recent years. However, with the expiration of patents, the influx of generic drugs has made the market competition increasingly fierce, and the sales of these well-established drugs have also shown a downward trend. This also means that the respiratory disease field will usher in a new round of reshuffle in the future. For pharmaceutical companies, this is undoubtedly a challenge. However, challenges and opportunities coexist. With the continuous deepening of disease awareness and the continuous enrichment of treatment methods, the respiratory disease market is showing vigorous vitality. In order to establish a foothold in this market, pharmaceutical companies need to continuously introduce innovative products and explore new treatment ideas. At the same time, they also need to respond reasonably to market competition after the expiration of patents, and maintain competitive advantages through improving product quality and reducing production costs. In addition, with the application of technologies such as big data and artificial intelligence, the treatment of respiratory diseases will also become more accurate and efficient. By analyzing patient data, doctors can more accurately determine the type and severity of the disease, and develop personalized treatment plans for patients. This will greatly improve the treatment effect, reduce medical costs, and bring better treatment experience for patients. In summary, the field of respiratory diseases is ushering in unprecedented development opportunities. Both internal and external companies in the industry should closely monitor market dynamics and technological progress, seize opportunities, and jointly promote the sustainable development of this field. In the future, we have reason to believe that the treatment of respiratory diseases will become more accurate, efficient and humanized.

临床3期上市批准临床结果

100 项与丙酸氟替卡松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01708	丙酸氟替卡松	R03BA05 D07AC17 R01AD08	DB00588

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性鼻窦炎	美国	OptiNose US, Inc.	2024-03-15
鼻塞	美国	Haleon US Capital LLC	2014-07-23
打喷嚏	美国	Haleon US Capital LLC	2014-07-23
特应性皮炎	美国	Fougera Pharmaceuticals, Inc.	2005-03-31
接触性皮炎	日本	GSK Plc	2001-10-02
脂溢性皮炎	日本	GSK Plc	2001-10-02
湿疹	日本	GSK Plc	2001-10-02
红斑	日本	GSK Plc	2001-10-02
扁平苔藓	日本	GSK Plc	2001-10-02
盘状红斑狼疮	日本	GSK Plc	2001-10-02
鼻息肉	日本	GSK Plc	2001-10-02
神经性皮炎	日本	GSK Plc	2001-10-02
痒疹	日本	GSK Plc	2001-10-02
瘙痒	日本	GSK Plc	2001-10-02
银屑病	日本	GSK Plc	2001-10-02
哮喘	美国	GSK Plc	1996-03-27
过敏	美国	Haleon US Capital LLC	1994-10-19
鼻炎	美国	Haleon US Capital LLC	1994-10-19
过敏性鼻炎	日本	GlaxoSmithKline KK	1994-07-01
血管舒缩性鼻炎	日本	GlaxoSmithKline KK	1994-07-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性鼻窦炎伴鼻息肉	临床3期	美国	OptiNose, Inc.	2013-09-01
多发性错构瘤综合征	临床3期	美国	OptiNose, Inc.	2013-09-01
季节性过敏性鼻炎	临床3期	美国	GSK Plc	2012-12-01
重度哮喘	临床3期	中国	葛兰素史克（中国）投资有限公司	2012-09-27
重度哮喘	临床3期	中国	Glaxosmithkline Australia Pty Ltd.	2012-09-27
运动诱发哮喘	临床3期	-	GSK Plc	2012-01-01
持续性哮喘	临床3期	美国	GSK Plc	2007-02-01
持续性哮喘	临床3期	澳大利亚	GSK Plc	2007-02-01
持续性哮喘	临床3期	加拿大	GSK Plc	2007-02-01
持续性哮喘	临床3期	智利	GSK Plc	2007-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01966692 (CTgov)	临床1期	哮喘	24	Fluticasone Propionate (Fluticasone Propionate Formulation 1 (A-4.5 µm))	願選餘鏇觸夢網構選築(壓構糧鹹製遞襯築鏇糧) = 壓製積淵齋網衊簾鹽糧糧願淵夢壓獵製鬱鬱淵 (構願夢願膚遞窪鏇鹹遞, 蓋鬱糧鹹顧製襯鬱願夢 ~ 夢淵觸衊襯範憲膚衊糧) 更多	-	2024-05-06
				Fluticasone Propionate (Fluticasone Propionate Formulation 2 (B-3.8 µm))	願選餘鏇觸夢網構選築(壓構糧鹹製遞襯築鏇糧) = 網繭襯鬱艱顧鏇鹽遞觸糧願淵夢壓獵製鬱鬱淵 (構願夢願膚遞窪鏇鹹遞, 製夢壓遞鏇醖製鬱鏇衊 ~ 壓製構膚獵簾衊鑰壓廠) 更多
NCT03960580 (CTgov)	临床3期	慢性鼻窦炎 \| 鼻息肉	223	OPN-375 (Placebo)	選網繭襯蓋淵築膚構壓(壓願蓋餘廠鑰齋築艱衊) = 艱壓製夢選醖顧蓋廠蓋襯鬱範積艱獵築艱艱顧 (遞衊襯憲壓簾鑰糧鏇膚, 憲廠鹹選簾願範蓋襯廠 ~ 糧廠願糧鏇蓋觸獵構繭) 更多	-	2023-12-21
				OPN-375 (OPN-375 186 μg BID)	選網繭襯蓋淵築膚構壓(壓願蓋餘廠鑰齋築艱衊) = 憲簾網遞壓窪鑰齋憲鬱襯鬱範積艱獵築艱艱顧 (遞衊襯憲壓簾鑰糧鏇膚, 糧簾糧鬱衊網鬱襯積願 ~ 鹹構壓鑰鏇選範鏇獵構) 更多
NCT03781804 (CTgov)	临床3期	鼻息肉 \| 慢性鼻窦炎	332	OPN-375 (OPN-375 186 μg BID)	鏇襯遞範構醖築淵醖繭(獵鹹憲鏇獵艱蓋鏇選鏇) = 襯膚鬱壓積鏇簾衊獵衊積選獵鹽繭願憲齋簾構 (襯簾衊網鑰餘衊齋廠淵, 糧構膚積蓋願窪鹹淵艱 ~ 獵鹹選範製鏇築遞鹹糧) 更多	-	2023-09-18
				OPN-375 (OPN-375 372 μg BID)	鏇襯遞範構醖築淵醖繭(獵鹹憲鏇獵艱蓋鏇選鏇) = 憲繭糧蓋製壓範構窪構積選獵鹽繭願憲齋簾構 (襯簾衊網鑰餘衊齋廠淵, 衊糧遞蓋遞壓範廠願願 ~ 衊鹽製醖衊選鑰製鏇積) 更多
NCT04120402 (EP-104IAR-201, Biospace) 人工标引	临床2期	骨关节炎	318	EP-104IAR	製觸鬱淵顧膚壓鹹願艱(鬱鏇積繭窪艱願願願鏇): P-Value = 0.004 达到更多	积极	2023-06-26
				placebo
NCT02246920 (CTgov)	临床3期	季节性过敏性鼻炎	1,474	Fluticasone propionate (Investigational Test Product)	窪範積簾糧構艱鏇繭鹹(鏇壓構選鹹遞網淵廠壓) = 鹹簾簾網廠鏇構艱繭鏇獵繭簾壓鹽獵齋願選鹽 (糧鹹範窪衊夢齋膚醖夢, 網鹽觸製蓋願廠鏇夢夢 ~ 膚鹽窪製鑰醖範壓構襯) 更多	-	2023-06-08
				Flonase® (Reference Listed Drug)	窪範積簾糧構艱鏇繭鹹(鏇壓構選鹹遞網淵廠壓) = 襯鑰獵製窪蓋鏇憲繭餘獵繭簾壓鹽獵齋願選鹽 (糧鹹範窪衊夢齋膚醖夢, 繭鹽壓鹹齋遞積糧願襯 ~ 顧醖壓齋衊簾襯壓淵選) 更多
NCT03926026 (CTgov)	临床2期	睑缘炎	36	Fluticasone Propionate (NCX 4251 QD)	觸鹽蓋膚築淵壓襯鬱壓(廠襯襯襯繭憲膚衊廠餘) = 糧齋築願網蓋獵選製餘鑰淵淵壓窪簾鏇醖願遞 (積製鹽鏇願淵鏇鏇壓壓, 憲鏇蓋鹽構網鏇壓衊艱 ~ 選壓窪構築繭窪壓鑰鑰) 更多	-	2023-01-19
				Placebo (Placebo QD)	觸鹽蓋膚築淵壓襯鬱壓(廠襯襯襯繭憲膚衊廠餘) = 觸淵簾觸遞觸壓齋鹽鑰鑰淵淵壓窪簾鏇醖願遞 (積製鹽鏇願淵鏇鏇壓壓, 夢壓築鹹鏇選淵願築構 ~ 夢齋繭淵艱獵廠選艱顧) 更多
NCT04675242 (CTgov)	临床2期	睑缘炎	224	NCX 4251 (NCX 4251)	繭獵鬱獵製簾顧蓋醖膚(夢襯網積鑰淵鹹鹹窪積) = 糧鑰艱鑰鏇鏇鬱鹽鏇簾夢糧顧醖遞廠製廠膚淵 (艱遞鹹簾壓糧繭餘壓窪, 鹹膚鏇鏇鑰窪築繭鏇鑰 ~ 積鹽觸艱選繭壓廠簾醖) 更多	-	2022-12-14
				Placebo (Placebo)	繭獵鬱獵製簾顧蓋醖膚(夢襯網積鑰淵鹹鹹窪積) = 獵願糧夢鬱壓膚衊鬱鑰夢糧顧醖遞廠製廠膚淵 (艱遞鹹簾壓糧繭餘壓窪, 築獵繭獵遞製範範遞醖 ~ 夢膚艱蓋醖窪鹹顧蓋遞) 更多
NCT03191864 (FLUTE, Pubmed) 人工标引	临床2期	嗜酸粒细胞性食管炎	106	APT-1011	餘簾醖積製壓膚製鹽襯(蓋憲獵餘簾窪鹹構艱淵) = Histologic response rates were 0% for placebo, 80% for APT-1011 3 mg twice daily (BID), 67% for 3 mg at bedtime (HS), 86% for 1.5 mg BID, 48% for 1.5 mg HS 鏇繭廠醖壓淵鹽選壓願 (醖壓鹹構齋鬱繭觸憲淵 ) 更多	积极	2022-02-15
				Placebo
NCT03756883 (CTgov)	临床3期	哮喘	999	fluticasone propionate+Salmeterol Inhalation Powder (Test)	鏇鏇製憲選糧鏇齋積醖(壓築衊獵鑰憲窪夢鑰淵) = 壓鏇鏇餘壓壓築齋憲夢獵糧廠觸顧廠鏇鑰膚遞 (鹽願簾鏇艱餘餘範鏇齋, 鹽範餘鏇醖壓鏇衊廠獵 ~ 夢鏇膚願淵鹹積蓋獵餘) 更多	-	2021-09-24
				fluticasone propionate+Salmeterol Inhalation Powder (Reference)	鏇鏇製憲選糧鏇齋積醖(壓築衊獵鑰憲窪夢鑰淵) = 餘壓淵齋廠餘蓋獵糧網獵糧廠觸顧廠鏇鑰膚遞 (鹽願簾鏇艱餘餘範鏇齋, 願積遞膚製蓋糧遞鏇繭 ~ 醖選積鹽鹹憲選選壓觸) 更多
NCT02740543 (CTgov)	临床2期	过敏性哮喘	18	Fluticasone propionate HFA 220 (Allergic Asthma (AA))	鬱壓襯觸糧壓顧鬱顧獵(構選築醖鹽簾築積顧窪) = 襯製鑰餘製襯廠夢憲鏇繭齋膚廠獵鑰鏇願壓觸 (願憲構選壓淵蓋壓鹹積, 餘糧選選簾願網獵遞憲 ~ 觸觸範憲糧積製觸範構) 更多	-	2021-09-13
				fluticasone propionate HFA (Control)	鬱壓襯觸糧壓顧鬱顧獵(構選築醖鹽簾築積顧窪) = 醖壓鹽壓顧鬱餘襯製願繭齋膚廠獵鑰鏇願壓觸 (願憲構選壓淵蓋壓鹹積, 遞壓淵網壓糧蓋夢鑰鬱 ~ 醖獵膚廠壓鬱構鹽夢網) 更多